HIV DNA vaccine (PENNVAX-GP) - Inovio

Drug Profile

HIV DNA vaccine (PENNVAX-GP) - Inovio

Alternative Names: PENNVAX-GP; Pennvax-GP; PENNVAX-GP DNA vaccine - Inovio/NIAID; PENNVAX®-GP HIV immunotherapy

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 24 May 2017 Efficacy data from a phase I trial in HIV infecctions released by Inovio
  • 30 Mar 2017 Inovio Pharmaceuticals plans a proof-of-concept clinical programme for HIV infections (Monotherapy, Combination therapy) in USA
  • 08 Aug 2016 National Institute of Allergy and Infectious Diseases completes enrolment in its phase I trial for HIV infections (In volunteers) in USA (NCT02431767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top